Breaking News

Rentschler Biopharma’s ATMP UK Facility Receives MHRA Approval

Facility offers services from early process and analytical development through cGMP manufacturing for clinical trials.

Rentschler Biopharma SE, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), has received the cGMP manufacturing compliance certificate, following the successful inspection by the UK Medicines & Healthcare Products Regulatory Agency (MHRA) at its UK site. The ATMP business was announced in early 2021 and the facility is located in the cell and gene therapy Catapult’s Manufacturing Innovation Centre...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters